Blueprint Medicines Q1 AYVAKIT revenue $92.5M, raises full-year guidance to $390-410M

Blueprint Medicines Corp

2024-Q1 EPS reported $1.40 revenue$96,116,000

AYVAKIT net product revenue $92.5M in Q1 2024, up >135% YoY from $39.1M.
Full-year AYVAKIT revenue guidance raised to $390-410M from prior $360-390M.
Net income of $89.1M includes a $173.7M non-cash debt extinguishment gain; prior year net loss $129.6M.
Cash, cash equivalents and investments $735.6M as of March 31, 2024, down from $767.2M at year-end 2023.
BLU-808 IND on track for Q2 2024; BLU-222 combination data to be presented at ASCO 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Blueprint Medicines Corp reported the first quarter ended March 31, 2024 results: revenue $92.5 million. Guidance raised.

Period: the first quarter ended March 31, 2024
Revenue: $92.5 million
Guidance: raised
Result: reported results

Exact text from the filing

-- Achieved $92.5 million in AYVAKIT net product revenues in the first quarter 2024 -- -- Raising guidance to $390 million to $410 million in full year AYVAKIT net product revenues --

View on SEC.gov

362 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001558370-24-006451

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.